Product Portfolio

OLEOGEL-S10 (AP101)

Oleogel-S10 (AP101) is Amryt’s lead development candidate, a potential treatment for Epidermolysis Bullosa (“EB”), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatments available.  Oleogel-S10 is currently in a Phase 3 clinical trial and recently reported positive unblinded interim efficacy and safety analyses.  It is anticipated this study will be fully enrolled by the end of 2019.

Tubes with liquid